← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #5 OF 1,000 MOST-CITED

Lack of or inadequate complaint procedures

FDA cited this observation 1,452 times across 1,323 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices1,452
BY FISCAL YEAR
FY202652
FY2025187
FY2024161
FY2023170
FY2022128
FY202147
FY2020130
FY2019225
FY2018208
FY2017144

How FDA worded it — real examples

Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.

Marson Medical, Inc. · Paramus, New Jersey · Devices · 2026-01-16

Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been established.

MIDWAY MEDICAL · Bloomington, Illinois · Devices · 2026-01-15

Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.

Apex Medical Technologies, Inc. · San Diego, California · Devices · 2026-01-15

Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.

Expanse Medical Inc. · Pleasanton, California · Devices · 2026-01-15

Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.

Conformis Inc. · Wilmington, Massachusetts · Devices · 2026-01-13

Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.

Innova Vascular Inc · Irvine, California · Devices · 2026-01-12

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Quality risk managementPharmaceutical quality systemMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →